Hematopoietic Stem Cell Transplantation For Patients With Acute Myeloid Leukemia:Clinical Observation In 40 Cases

Objective To investigate the clinical efficacy and complication of hematopoietic stem cell transplantation for acute myeloid leukemia.Methods 40 patients received HSCT,14 patiens were treated with auto-HSCT and 26 patients with allo-HSCT. In 26 cases who accepted allo-HSCT from siblings,19 cases were HLA-identical(6/6), Three were 2 HLA-antigen mismatched(4/6),4 cases were 3 HLA-antigen mismatched(3/6).Results 38 of 40 patients reconstituted hematopoiesis,with the median time of graft survival of neutrophils and platelets being 12 d vs 14 d and 14 d vs 20 d in auto-HSCT and allo-HSCT groups. The incidences of HVOD,HC and CMV were 0%,25% and 10%,respectively. The incidence of Acute GVHD was 23.1% and of cGVHD was 30.8%.27 cases were disease-free survival from 1to 47 monthe.,and 6 cases were disease relapse.Conclusion HSCT is safe and an only effective approach for the cure of patients with AML. In the case of can’t find the donor, auto-HSCT can be used as a consolidation treatment after CR, achieve the goal of prolong patient life. Compared with auto-HSCT,allo-HSCT,the recurrence rate is low, the majority of patients can get clinical cure.For refractory AML, allo-HSCT is the only hope for cure. Finally,if there are no human leukocyte antigen-identical sibling donors,haploidentical HSCT is an effective and feasible treatment for patient with acute myeloid leukemia.